

Amendments to the Claims:

1-12. (Canceled)

13. (Currently amended) An Isolated-isolated polypeptide comprising a clone 65 polypeptide having at least a 90% sequence identity to the sequence of SEQ ID NO: 3 or SEQ ID NO:6, encoded by the nucleic acid of claim 1 wherein the expression of said polypeptide is induced by Wnt-1.

14. (Currently amended) The polypeptide of claim 13 ~~that is comprising~~ a human clone 65 polypeptide of SEQ ID NO: 3 or a mouse clone 65 polypeptide of SEQ ID NO: 6.

15. (Currently amended) An Isolated-isolated clone 65 polypeptide encoded by a nucleic acid of claim 9 comprising SEQ ID NO:11, 12, 13, 14, 15, 16, 17, 18, or 19.

16. (Currently amended) A chimeric molecule comprising a ~~clone 65-polypeptide of~~ claim 13, 14, 15, or 44 fused to a heterologous amino acid sequence.

17. (Previously presented) The chimeric molecule of claim 16 wherein said heterologous amino acid sequence is an epitope tag sequence or an Fc region of an immunoglobulin.

18-37. (canceled)

38. (Previously presented) A composition comprising the polypeptide of claim 13 and a carrier therefor.

39. (Canceled)

40. (Currently amended) A composition comprising the polypeptide of claim 14, claim 15, or claim 44 and a carrier therefor.

41-43. (Canceled)

44. (New) An isolated clone 65 polypeptide that is human clone 65 polypeptide of SEQ ID NO: 3 or mouse clone 65 polypeptide of SEQ ID NO: 6.